Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Sponsor: Novo Nordisk A/S
Summary
In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors but has previously been tested in humans. The study is split into 2 parts. In the first part of the study, participants will either get CagriSema or a weight loss diet (calorie reduced). In the second part of the study,all participants will get CagriSema. Which treatment participants get in the first part of the study is decided by chance. Like all medicines, the study medicine may have side effects. The study will last for about 1.5 years.
Official title: The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised Study
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-09-26
Completion Date
2027-10-12
Last Updated
2025-10-08
Healthy Volunteers
No
Conditions
Interventions
CagriSema (Cagrilintide B + semaglutide I)
Cagrilintide and semaglutide will be administered subcutaneously.
Low Energy Diet
Participants will receive dietary intervention as per diet intervention manual.
Locations (2)
Advent Health-Res Inst
Orlando, Florida, United States
Pennington Biomed Res Ctr
Baton Rouge, Louisiana, United States